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Summary
Background.— Premature discontinuation of and reduced adherence to antiplatelet therapy
have been identiﬁed as major risk factors for stent thrombosis and poor prognosis after acute
coronary syndrome.
Aim.— We aimed to identify correlates of non-adherence to aspirin among patients who had
undergone coronary stenting.
Methods.— We prospectively included all patients who had undergone coronary stenting in our
institution. Response to aspirin was assessed during the hospital phase with arachidonic acid-
induced platelet aggregation (AA-Ag) and only good responders to aspirin (AA-Ag < 30%) were
included in the study for longitudinal assessment (n = 308). Response to aspirin was reassessed
Abbreviations: AA, arachidonic acid; AA-Ag, arachidonic acid-induced platelet aggregation; AUC, area under the receiver operating
haracteristic curve; ROC, receiver operating characteristic.
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1 month after hospital discharge and non-responders received a directly observed intake of
aspirin to exclude any biological non-response due to bioavailability problems. After excluding
patients with such problems, response to aspirin based on platelet function testing was used
to estimate non-adherence to aspirin after coronary stenting. A logistic regression model was
used to identify predictors of non-adherence.
Results.— Non-adherence to aspirin concerned 14% of the study sample (n = 43). After adjust-
ment for age, those who reported the highest risk of non-adherence to aspirin were migrants
(odds ratio [95% conﬁdence interval], 8.3 [3.5—19.8], followed by patients receiving treatment
for diabetes (4.5 [1.9—10.9]). Smokers had a threefold risk of non-adherence (3.1 [1.4—6.9]).
Conclusions.— Non-adherence to aspirin is relatively frequent in populations at high risk of
cardiovascular events. Appropriate case management and special interventions targeting these
groups need to be implemented to avoid fatal events and assure long-term adherence to treat-
ment.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé L’arrêt prématuré et la mauvaise adhérence aux antiplaquettaires ont été clairement
identiﬁés comme des facteurs de risque majeurs de thrombose de stent et de pronostic défa-
vorable après syndrome coronarien aigu. L’objectif de ce travail était d’identiﬁer des facteurs
de risque de mauvaise adhérence à l’aspirine après stenting coronarien. Trois cent huit patients
consécutifs bénéﬁciant d’une angioplastie coronaire ont été inclus, si leur réponse à l’aspirine
à l’hôpital, évaluée par l’agrégation à l’acide arachidonique (AA-Ag) était satisfaisante (AA-
Ag < 30%). La réponse à l’aspirine était réévaluée un mois plus tard en consultation et les
« non-répondeurs » recevaient une prise contrôlée d’aspirine pour identiﬁer les patients non
adhérents. Quarante-trois patients (14 %) étaient identiﬁés comme non adhérents. Une régres-
sion logistique était utilisée pour déterminer les facteurs de non-adhérence. Après ajustement
par l’âge, les facteurs de risque de non-adhérence étaient : le caractère migrant des patients
(OR [95 % intervalle de conﬁance], 8,3 [3,5—19,8]), les patients traités pour un diabète (4,5
[1,9—10,9]) et le tabagisme actif (3,1 [1,4—6,9]). En conclusion, la mauvaise adhérence à
l’aspirine est assez fréquente après angioplastie coronaire avec des facteurs de risque identiﬁés
rendant nécessaire le renforcement de l’éducation de ces populations à risque.
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Background
Platelet inhibition with aspirin and clopidogrel has sig-
niﬁcantly reduced recurrent ischaemic events after both
coronary stenting and non-ST-segment elevation acute coro-
nary syndrome [1,2]. Nevertheless, ischaemic events still
occur in clinical practice, and for patients treated with
aspirin these events have been attributed by some inves-
tigators to aspirin resistance [3]. Aspirin resistance, usually
assessed by arachidonic acid (AA)-induced platelet aggre-
gation (AA-Ag), has been widely investigated [3] and is
associated with adverse clinical outcomes [4—8]. Several
mechanisms have been proposed for this wide variability
in antiplatelet therapy response, including polymorphisms
in platelet receptor genes, interaction with medication
and malabsorption [3]. However, the primary reason for
inadequate platelet inhibition in patients treated with
aspirin is non-adherence. As non-adherence to aspirin
is often mistaken for aspirin resistance, platelet func-
tion testing is used to assess adherence to aspirin only
after exclusion of patients with real bioavailability prob-
lems and biological aspirin resistance [9]. Using this same
method to detect non-adherent patients, we aimed to
identify clinical and social risk factors for non-adherence
to aspirin in patients who had undergone coronary stent-
ing.
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ds droits réservés.
ethods
tudy population and design
ll patients admitted to the Department of Cardiology at
a Timone Hospital in Marseilles between September 2008
nd June 2009 were considered eligible to enter the study
f they had: chronic therapy with aspirin 75mg for at least 1
eek; undergone coronary stenting for non-ST-segment ele-
ation acute coronary syndrome; a good in-hospital aspirin
esponse deﬁned by AA-Ag less than 30%.
The exclusion criteria were as follows: history of bleeding
iathesis; acute coronary syndrome less than 4 days; glyco-
rotein IIb/IIIa antagonist less than 48 h; New York Heart
ssociation class IV; contraindications to antiplatelet ther-
py; platelet count less than 100G/L; creatinine clearance
ess than 30mL/min; and low response to aspirin during the
ospital phase (AA-Ag > 30%).
Patients received non-enteric coated aspirin 75mg daily
s a directly-observed therapy administered by a nurse dur-
ng hospitalization, to minimize the risk of non-adherence
ssociated with daily clopidogrel 150mg. After 3 days,
he ‘in-hospital aspirin response’ was measured within
2 hours after each aspirin intake using AA-Ag. Patients were
ischarged with a prescription of aspirin 75mg and clopi-
ogrel 150mg daily and were provided with educational
308 T. Cuisset et al.
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wigure 1. Study design.
essions highlighting the importance of patient adherence
o physicians’ recommendations. One month after hospi-
al discharge, patients were admitted to our Antiplatelet
onitoring Unit and were asked if they were actually tak-
ng their medication. Assessment of ‘outpatient response
o aspirin’ with AA-Ag was then performed between 1 and
2 h after each aspirin intake. Patients identiﬁed as non-
esponders received directly observed aspirin therapy 75mg
efore reassessment on the same day, 1 to 12 h after admin-
stration, in order to exclude bioavailability problems and
o properly identify non-adherent patients (Fig. 1). Patients
ave written informed consent for participation.
latelet variableslood samples were drawn from a peripheral venous
atheter. The platelet count was determined in the platelet-
ich plasma sample and adjusted to 2.5× 108 mL−1 with
omologous platelet-poor plasma. Platelets were stimulated
P
t
e
aith AA (0.5mg/mL) and aggregation was assessed with a
AP4 aggregometer (Biodata Corporation, Wellcome, Paris,
rance). Aggregation was expressed as the maximal percent-
ge change in light transmittance from baseline with the
latelet-poor plasma as reference. Here we report data on
aximal intensity of platelet aggregation with AA concen-
ration. The coefﬁcient of variation of maximal intensity
f platelet aggregation with AA was 6%. Non-response to
spirin was deﬁned by AA-Ag greater than 30%, as described
reviously [5].
tatistical analysis
tatistical analyses were performed using the SPSS soft-
are program, version 15.0 (SPSS Inc., Chicago, IL, USA).
otential risk factors and patients’ social and clinical charac-
eristics were screened for inclusion in the model by testing
ach independently for any signiﬁcant association with non-
dherence, using univariate logistic regression. Variables
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Table 1 Sociodemographic risk factors and medical characteristics of patients stratiﬁed according to non-adherence to
aspirin (n = 308).
Categorical
variables
Modality All patients (n = 308) Non-adherence to aspirin
No (n = 265) Yes (n = 43)
Sex Female 59 (19) 52 (20) 7 (16)
Male 249 (81) 213 (80) 36 (84)
Free health care for
people on low
incomes
No 295 (96) 257 (97) 38 (88)
Yes 13 (4) 8 (3) 5 (12)
Migrant Native individuals 276 (90) 247 (93) 29 (67)
Immigrant individuals 32 (10) 18 (7) 14 (33)
Body mass index ≤ 25 119 (39) 107 (41) 12 (28)
> 25 118 (61) 157 (60) 31 (72)
Family history of
coronary artery
disease
No 221 (72) 184 (70) 37 (86)
Yes 86 (28) 80 (30) 6 (14)
Smoker No 171 (56) 153 (58) 18 (42)
Yes 136 (44) 111 (42) 25 (58)
Beta-blocker No 94 (31) 77 (29) 17 (40)
Yes 214 (69) 188 (71) 26 (60)
Statins No 20 (6) 16 (6) 4 (9)
Yes 288 (94) 249 (94) 39 (91)
Treated for diabetes No 273 (89) 241 (91) 32 (74)
Yes 35 (11) 24 (9) 11 (26)
Age (years) 63± 12 63± 12 65± 11
Data are number (%) or mean± standard deviation.
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sthat achieved a liberal signiﬁcance level of p≤ 0.25 in the
univariate analysis were included in the multivariate model.
For the multivariate analysis, a logistic regression based on a
backward elimination approach was used and variables were
considered to be signiﬁcantly associated with the outcome if
the p value was less or equal to 0.05. A good way of assessing
a binary logistic regression model’s ability to accurately clas-
sify observations is to use a receiver operating characteristic
(ROC) curve. A ROC curve is constructed by generating sev-
eral classiﬁcation tables for cut-off values ranging from 0 to
1, and calculating the sensitivity (proportion of truly non-
adherent patients who were correctly identiﬁed as such)
and speciﬁcity (proportion of truly adherent patients who
were correctly identiﬁed as such) for each threshold value.
Sensitivity is plotted against 1− speciﬁcity (i.e. one minus
speciﬁcity) to create a ROC curve.
The area under the ROC curve (AUC) is commonly used
as a summary measure of the receiver operating charac-
teristic curve and provides a measure of discrimination:
a model with a large area under the ROC curve suggests
that the model is able to accurately predict the value
of an observation’s response. Hosmer and Lemeshow have
provided general rules for interpreting AUC values [10]:
AUC= 0.5, no discrimination; 0.7 ≤ AUC< 0.8, acceptable
discrimination; 0.8 ≤ AUC< 0.9, excellent discrimination;
AUC ≥ 0.9, outstanding discrimination (this is extremely
rare).
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aesults
mong all those who had undergone coronary stenting, 308
atients who fulﬁlled the enrolment criteria were included
n our study. After verifying possible bioavailability prob-
ems, non-adherent patients accounted for 14% of the study
ample (n = 43). The distribution of non-adherence in terms
f sociodemographic variables and medical characteristics
f the study population is summarized in Table 1. Mean
ge± standard deviation was 63± 12 years, men accounted
or the 81% of the sample, 4% beneﬁted from free public
ealth care because of their low incomes and 10% were
orn outside France (migrants). Thirty-ﬁve patients (11%)
ere receiving treatment for diabetes and 69% were receiv-
ng beta-blockers; converting enzyme inhibitors were being
sed by 74% patients and 94% were using statins. Moreover,
ore than 60% of patients had a body mass index greater
han 25 and 44% were smokers.
Table 2 presents results from the univariate and multi-
ariate analyses. Almost all the factors described previously
ad a p value below the 0.25 threshold in the univariate
nalysis; the only two variables that were not eligible were
ex and use of statins. The factors most associated with non-
dherence to aspirin were being a migrant and being treated
or diabetes. Results from the multivariate model concern-
ng independent factors associated with non-adherence to
spirin revealed that migrants exhibited the highest risk of
310 T. Cuisset et al.
Table 2 Factors associated with non-adherence to aspirin: univariate and multivariate analyses (n = 308).
Explanatory
variables
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Sex Female 1 0.61
Male 0.80 0.34—1.89
Free health care for
people on low
incomes
No 1 0.02
Yes 4.23 1.31—13.59
Migrant Native individuals 1 < 0.001 1 < 10—3?
Immigrant individuals 6.62 2.98—14.70 8.35 3.52—19.82
Body mass index ≤ 25 1 0.12
> 25 1.76 0.86—3.58
Family history of
coronary artery
disease
No 1 0.03
Yes 0.37 0.15—0.92
Smoker No 1 0.05 1 0.005
Yes 1.91 1—3.68 3.10 1.40—6.88
Beta-blocker No 1 0.17
Yes 0.63 0.32—1.22
Statins No 1 0.42
Yes 0.63 0.20—1.97
Treated for diabetes No 1 0.003 1 0.001
Yes 3.45 1.55—7.71 4.51 1.87—10.85
Age 1.02 0.99—1.04 0.24 1.04 1.01—1.08 0.02
n
v
n
C
F
uCI: conﬁdence interval; OR: odds ratio.on-adherence to aspirin (odds ratio [95% conﬁdence inter-
al]: 8.3 [3.5—19.8]), while smokers had a threefold risk of
on-adherence compared with non-smokers (3.1 [1.4—6.9]).
oprescription for diabetes signiﬁcantly increased the like-
igure 2. Discriminatory performance of the multivariate model
sing the receiver operating characteristic (ROC) curve.
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bihood of non-adherence by a factor greater than four (4.5
1.9—10.9]). We also evaluated the discriminatory perfor-
ance of the ﬁnal statistical model: the AUC was 0.78 (95%
onﬁdence interval [0.70—0.85]), which is an acceptable dis-
rimination according to Hosmer and Lemeshow [10] (Fig. 2).
iscussion
he results from the present study suggest that there is a
igh rate of non-adherence to aspirin in patients treated
or coronary stenting during the ﬁrst month after hospital
ischarge. The study identiﬁes speciﬁc groups at high risk
f non-adherence and, as a consequence, reduced response
o treatment leading to possible fatal events. The study
lso identiﬁes subgroups (such as migrants or individuals
lready receiving chronic treatments, such as patients with
iabetes) requiring specialized interventions for improving
dherence.
It has already been shown that non-adherence to
spirin is associated with recurrent ischaemic events, while
he independent effect of adherence on mortality after
myocardial infarction has been consistently shown in
ifferent studies [11,12]. More recently, premature discon-
inuation of antiplatelet therapy has been identiﬁed as the
reatest risk factor for stent thrombosis [13]. The rela-
ively high prevalence of patients non-adherent to aspirin
uggests that all those undergoing coronary stenting should
e targeted for aggressive and repeated educational ses-
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sions to ensure better adherence and sustained response to
treatment. Our results are consistent with previous stud-
ies conducted in the ﬁeld of adherence to thienopyridine
[14,15], where a lack of secondary school education was
associated with a higher risk of treatment withdrawal.
This suggests that early interventions for patients with less
formal education (such as migrants) should be reinforced
and diversiﬁed to ensure that they fully appreciate that
adherence to prescriptions is a crucial issue for survival.
These results may also inﬂuence daily practice and may
advocate the systematic use of platelets tests to better
monitor patients at risk of non-adherence or of being lost
to follow-up. Moreover, as there is quite a strong associa-
tion between non-adherence and the identiﬁed risk factors,
effective interventions targeting these populations in the
maintenance phase of treatment, as well as appropriate
case management, could drastically reduce the risk of non-
adherence and possible recurrent cardiovascular events.
Previous investigations showing that a strong belief by
patients in the necessity of their medications is a predic-
tor of long-term adherence, in turn support the idea that
physicians need to be vigilant in explaining the importance
of sustained adherence to medications [16]. To achieve this
aim, a rehabilitation programme after hospital discharge
might be very helpful in improving patient comprehension
and education. As side effects have already been found to
be associated with reduced adherence to aspirin [17], our
ﬁndings also underline the importance of both education
and management of side effects in daily clinical practice
and appropriate case management of patients affected by
other comorbidities requiring chronic treatment. The rare
occurrence of aspirin resistance in the present study strongly
suggests that its occurrence in previous literature has been
overestimated due to both adherence-related issues and the
use of non-speciﬁc platelet tests such as PFA-100.
The concept of aspirin resistance has emerged as a poten-
tial risk factor for recurrent cardiovascular events [4—8].
Several mechanisms have been proposed to explain the vari-
ability of platelet inhibition with aspirin [3]. A recent review
suggested a rate of aspirin non-responders of 28%, based
on different functional platelet tests [18]. However, before
estimating the response to antiplatelet therapy using var-
ious tests, the risk of a patient’s non-adherence should
be appropriately assessed. While different tools are avail-
able to assess aspirin non-adherence, such as platelet tests
and metabolite dosing, no study has yet used patient self-
reporting to assess it [6,8]. As self-reported adherence may
be under-reported because of social desirability bias, a sim-
ple self-reported measure may not be effective enough to
identify non-adherent patients. It is possible therefore that
in order to accurately assess adherence to aspirin using
self-reports, a special tool would need to be developed.
Such tools are already being used to measure adherence
to other chronically administered treatments (e.g. for dia-
betes, asthma and human immunodeﬁciency virus infection)
[19,20]. In our study, we observed an association between
age and non-compliance. This ﬁnding has already been
reported in a previous study by Tuppin et al. [21].In this study, we demonstrated the additional value of
platelet function testing for identiﬁcation of non-adherent
patients. AA-Ag is an excellent qualitative assay for the
detection of platelet inhibition by aspirin. A single dose311
f aspirin, even lower than 100mg, will inhibit AA-Ag for
ore than 48 h. Accordingly, the patients identiﬁed as non-
dherent had not followed the prescription for at least 3
ays. In our previous study [9], we already observed that
elf-reported non-compliance to aspirin is not effective and
hat AA-Ag is probably the best qualitative method for
etecting aspirin compliance. In the next few years, a dif-
erent formulation of aspirin (e.g. polypill), rather than the
owder formulation, may be required and may also be tested
sing self-reports to assess adherence.
tudy limitations
ome limitations need to be acknowledged. This was a single
entre study from a southern European country. However,
s access to care is free for the French population, it is
nlikely that most marginalized populations were under-
epresented. The data collection included only a limited
umber of factors and it is possible that important predic-
ors may have been not revealed by this analysis. We did
ot simultaneously assess non-adherence to clopidogrel, as
o distinguishing platelet function tests are currently able
o discriminate non-responders from non-adherent subjects.
his is because of the wide variability of platelet response
o clopidogrel in adherent patients.
onclusions
ur results illustrate that after identifying non-responders
o aspirin in patients undergoing coronary stenting,
on-adherence behaviours should be detected and pre-
ented before treatment with alternative and/or additional
ntiplatelet medications. Future research should focus on
he evaluation of future interventions to improve adherence
n at-risk populations —particularly multitreated patients—
specially in the initial phase, which remains the most crit-
cal period for this population.
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